Cushing’s Syndrome Therapeutics Analysis, Clinical Trials and Developments

Press Release

Cushing’s syndrome therapeutics currently exhibits a proliferating pipeline with 15+ therapeutic candidates.

Overproduction of cortisol hormone leads to Cushing’s syndrome. Also, exposure to glucocorticoids is expected to be one of the prime causes of the disease. Glucocorticoids are usually prescribed for diseases such as asthma, rheumatoid arthritis (RA), and lupus. Pituitary tumor, adrenal tumors, and ectopic adrenocorticotropic hormone (ACTH)-producing tumors result in increased cortisol level, eventually becoming a cause for Cushing’s syndrome. According to the American Association of Neurological Surgeons (AANS) 2019 factsheet, Cushing’s syndrome is more common in females than males and majorly affects adults aged 20–50 years.

Pre-Purchase Inquiry at:

There are several companies that are involved in developing therapeutics for Cushing’s syndrome have shown positive results of clinical trials. For instance, in March 2019, Strongbridge Biopharma plc announced positive results of extended evaluation phase of the pivotal Phase III Sonics study of Recorlev, a cortisol synthesis inhibitor. According to the results of the study, Recorlev demonstrated long-term efficacy to reduce mean urinary free cortisol (mUFC), as well as cardiovascular risk markers such as weight and low-density lipoprotein (LDL)-cholesterol.

Some key players involved in the development of Cushing’s syndrome therapeutics include Novartis AG, AstraZeneca PLC, Diurnal Group PLC, Corcept Therapeutics Incorporated, Crinetics Pharmaceuticals Inc., Strongbridge Biopharma plc, and Spruce Biosciences Inc.

Cushing’s Syndrome Therapeutics Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

This post was originally published on Financial Sector

Comments are closed.